-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0543_05-24-2013.pdf
January 01, 2013 - populations, interventions, comparators, and outcomes, will be further developed in the
refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0407_01-20-2011.pdf
January 01, 2011 - populations, interventions, comparators, and outcomes, will be further developed in
the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0264_01-14-2008.pdf
January 01, 2008 - populations, interventions, comparators, and
outcomes, will be further developed in the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0416_02-18-2011.pdf
January 01, 2011 - populations, interventions, comparators, and outcomes, will be further developed in
the refinement phase
-
effectivehealthcare.ahrq.gov/products/wiki-collaboration/research
September 30, 2011 - Feasibility Study of a Wiki Collaboration Platform for Systematic Reviews
Research Report September 30, 2011 Web Version [NLM Site] Download Main Document PDF 643.7 KB
People using assistive technology may not be able to fully access information in this file. For additional assistance, please contact u…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0620_131115.pdf
March 13, 2013 - populations, interventions, comparators, and outcomes, will be further developed in
the refinement phase
-
effectivehealthcare.ahrq.gov/products/prostatic-hyperplasia-medications/research-protocol
April 24, 2015 - adrenergic agonist
Increases bladder capacity by relaxing the bladdersmooth muscle during the storage phase … random allocation/
double blind method/
single blind method/
clinical trial/
clinical trial, phase … clinical trial, phase ii.pt.
clinical trial, phase iii.pt.
clinical trial, phase iv.pt. … Effects and Adverse Reactions"/
exp Adverse Drug Reaction Reporting Systems/
exp Clinical Trials, Phase … Effects and Adverse Reactions"/
exp Adverse Drug Reaction Reporting Systems/
exp Clinical Trials, Phase
-
effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1406.pdf
June 01, 2014 - inclusion are those interventions expected to be within 0–3 years of potential diffusion (e.g., in
phase … Results
The table below lists the one topic for which (1) preliminary phase III data for drugs were … Phase III trials conducted to
obtain FDA approval reported that patients with SBS treated with teduglutide … Of the 566 subjects, 173 subjects were treated in Phase 3 SBS
studies (134/173 [77%] at the dose of … Phase 3 Gattex (teduglutide) data highlight
potential new treatment for adults with short bowel
syndrome
-
effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1412.pdf
February 01, 2015 - inclusion are those interventions expected to be within 0–3 years of potential diffusion (e.g., in
phase … Results
The table below lists the two topics for which (1) preliminary phase III data for drugs were … this period, primarily due to failure to meet stated
endpoints or demonstrate treatment efficacy in phase … and two beta-amyloid precursor
protein site–cleaving enzyme (BACE) inhibitors, currently in late-phase … The latter cooperative sponsors the largest ongoing trial, a phase II/III trial
investigating intranasal
-
effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
December 01, 2015 - inclusion are those interventions expected to be within 0–3 years of potential diffusion (e.g., in
phase … Results
The table below lists the four topics for which (1) preliminary phase III data for drugs or … Recently completed unphased,
phase II, and phase IV clinical studies reported that daily oral zonisamide … In a phase III
trial sponsored by the University of Pittsburgh (Pittsburgh, PA) and its affiliated … , a University of Pittsburgh (Pittsburgh, PA)-based research group reported results
from a larger phase
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/head-neck-cancer_disposition-comments.pdf
May 27, 2010 - The reference is:
First results of a phase III multicenter randomized controlled trial of intensity … All three randomized studies, as well as all phase II-like
and retrospective comparisons, report improved … Besides careful phase I-II studies of dose
escalation, a policy of delivering higher doses using IMRT … In addition, two phase III
RTOG trials (0522 and 0234) have 3DRT and IMRT treatment populations which … Besides careful
phase I-II studies of dose escalation, a policy of delivering higher doses using
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0368_11-08-2010.pdf
January 01, 2010 - populations, interventions, comparators, and outcomes, will be further developed in the
refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0367_11-08-2010.pdf
January 01, 2010 - populations, interventions, comparators, and
outcomes, will be further developed in the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0129_07-13-2009.pdf
January 01, 2009 - populations, interventions, comparators, and outcomes, will be further developed in
the refinement phase
-
effectivehealthcare.ahrq.gov/products/distributed-network-expansion/research
April 03, 2012 - The enhancements described below will be incorporated into Phase 2 of our Distributed Research Network … We designated this activity as Phase 1.5, to distinguish it from the task order that ended in August … Our approach was based on lessons learned from Phase 1 of DRN and specifically on our findings that a … Data Mart Client Functions
Workflow Manager— In this phase, the Data Mart Client was extended so that … Document Scope
This document describes the functional requirements and design for DRN phase 1.5.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_disposition-comments.pdf
September 01, 2011 - In adverse event
analysis, page 45, why weren't open label run-in phase data in the
withdrawal studies … This was a 3-
phase study (Period A) was a 4-month, open-label phase that
determined response to abatacept … The
second phase (Period B) was a 6-month, randomized, double-blind,
parallel-dosing, placebo-controlled … During the double-blind phase
(Period B), serious adverse events occurred in two patients in the
placebo … E.g., the etanercept study
(Lovell, et al.) used an active run-in phase before randomization.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0710-140625.pdf
January 08, 2014 - populations, interventions, comparators, and outcomes, will be further
developed in the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0313_02-09-2009.pdf
January 01, 2009 - populations, interventions, comparators, and outcomes, will be further
developed in the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0075_03-10-2009.pdf
January 01, 2009 - populations, interventions, comparators, and
outcomes, will be further developed in the refinement phase
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0311_06-17-2008.pdf
January 01, 2008 - populations, interventions, comparators, and outcomes, will be further developed in
the refinement phase